INTERNATIONAL BIOTECHNOLOGY TRUST PLC - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.

Quarter-by-quarter ownership
INTERNATIONAL BIOTECHNOLOGY TRUST PLC ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q4 2021$905,000
-24.6%
67,0000.0%0.20%
-30.3%
Q3 2021$1,201,000
+4.5%
67,0000.0%0.29%
-4.3%
Q2 2021$1,149,000
-14.3%
67,0000.0%0.30%
-14.4%
Q1 2021$1,340,000
+17.6%
67,0000.0%0.35%
+13.8%
Q4 2020$1,139,000
+2.6%
67,0000.0%0.31%
-13.1%
Q3 2020$1,110,000
-26.0%
67,0000.0%0.36%
-28.1%
Q2 2020$1,499,000
+25.6%
67,0000.0%0.50%
-8.5%
Q1 2020$1,193,000
-60.5%
67,000
-52.1%
0.54%
-50.0%
Q4 2019$3,021,000
+176.4%
140,000
+133.3%
1.09%
+115.4%
Q3 2019$1,093,000
-48.8%
60,0000.0%0.50%
-36.2%
Q2 2019$2,135,000
+5.9%
60,0000.0%0.79%
+6.3%
Q1 2019$2,016,000
+30.2%
60,0000.0%0.74%
-22.5%
Q4 2018$1,548,000
-87.7%
60,000
-71.6%
0.96%
-78.4%
Q4 2017$12,597,000
+794.7%
211,000
+251.7%
4.44%
+723.9%
Q1 2017$1,408,000
+91.3%
60,0000.0%0.54%
+62.3%
Q4 2016$736,00060,0000.33%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q1 2022
NameSharesValueWeighting ↓
Camber Capital Management LP 3,500,000$60,060,0002.02%
ACT CAPITAL MANAGEMENT, LLC 161,500$2,772,0001.42%
Rhenman & Partners Asset Management AB 950,000$16,302,0001.11%
MAVERICK CAPITAL LTD 5,761,073$98,860,0000.93%
Birchview Capital, LP 72,000$1,236,0000.74%
Bellevue Group AG 4,101,404$70,380,0000.69%
CM Management, LLC 50,000$858,0000.62%
Duquesne Family Office 1,000,000$17,160,0000.42%
OSTERWEIS CAPITAL MANAGEMENT INC 373,368$6,407,0000.33%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 67,000$1,149,0000.30%
View complete list of NEKTAR THERAPEUTICS shareholders